Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

– Conference Call and Webcast to Follow at5:00 p.m. ET/2:00 p.m. PT–

ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 22, 2026--Exelixis, Inc.(Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released onWednesday, August 5, 2026after the markets close. At5:00 p.m. ET/2:00 p.m. PT,Exelixismanagement will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company’s website.

To access the conference call, please dial (800) 715-9871 (domestic) or (646) 307-1963 (international). TheExelixisconference call ID number is 5587241. To access the live webcast link, log ontowww.exelixis.comand proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will be archived onwww.exelixis.comfor one year.

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX®(cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visitwww.exelixis.com, follow@ExelixisIncon X (Twitter), likeExelixis, Inc.on Facebook and followExelixison LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260722931824/en/

Source: Exelixis, Inc.